Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5126795 | 0.99 | CHRNB4 (0.53) | CHRNB4CHRNA3MAPTNLRP3CYP2C9 | |
| SCHEMBL5015653 | 0.94 | CHRNB4 (0.52) | CHRNB4CHRNA3MAPTNLRP3KCNH2 | |
| Ammonia Solution, Strong SCHEMBL5129561 | 0.92 | CHRNB4 (0.51) | CHRNB4CHRNA3MAPTNLRP3KCNH2 | |
| Hydrochloric Acid SCHEMBL3221936 | 0.92 | CHRNB4 (0.51) | CHRNB4CHRNA3MAPTNLRP3KCNH2 | |
| SCHEMBL895210 | 0.88 | CHRNB4 (0.54) | CHRNB4CHRNA3MAPTNLRP3CYP2C9 | |
| SCHEMBL5012160 | 0.85 | CHRNB4 (0.50) | CHRNB4CHRNA3MAPTNLRP3RECQL | |
| SCHEMBL3089912 | 0.80 | TDP1 (0.40) | CHRNB4CHRNA3MAPTCYP2C9 | |
| SCHEMBL15855895 | 0.79 | MAPT (0.51) | CHRNB4CHRNA3MAPTRECQLDRD2 | |
| SCHEMBL14702502 | 0.79 | NLRP3 (0.44) | CHRNB4CHRNA3MAPTNLRP3KCNH2 | |
| Hydrochloric Acid SCHEMBL5015691 | 0.78 | MAPT (0.50) | CHRNB4CHRNA3MAPTRECQLDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8772307-B2 | Substituted spiro compounds and their use for producing pain-relief medicaments | GRUENENTHAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1888596-A1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122770-A1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | INA, SCN1A, SI | CHRNB4 719/4885CHRNA3 764/4885MAPT 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.